Clinical trials: Vascular Conditions
Chest Pain, Coronary Artery Disease
Risk Markers in the Acute Coronary Syndromes
The main aim of this trial is to assess the long-term prognostic value of different types of Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the emergency unit, employing blood samples…
- Conditions
- Chest Pain, Coronary Artery Disease, Unstable Angina Pectoris, Myocardial Infarction
- Trial name
- RACS (NCT00521976)
- Where
- Norway
- Volunteers
- 871 people
- Sponsor
- Helse Stavanger HF
Stroke, Atrial Fibrillation
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in…
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Trial name
- EngageAFTIMI48 (NCT00781391)
- Testing
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg)
- Where
- 1,009 sites in United States, Argentina and 44 more
- Volunteers
- 21,105 people
- Sponsor
- Daiichi Sankyo
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Coronary Artery Disease, Left Ventricular Dysfunction
DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation
This trial is a prospective, multi-center, randomized study of patients with coronary artery disease (CAD) and mild to moderate left ventricular (LV) dysfunction.
- Conditions
- Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
- Trial name
- DETERMINE (NCT00487279)
- Testing
- Defibrillator, Control
- Where
- 56 sites in United States
- Volunteers
- 81 people
- Sponsor
- Abbott Medical Devices
Angina, Coronary Occlusion
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
The objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and…
- Conditions
- Angina, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Stenosis
- Trial name
- NCT01721096
- Testing
- XIENCE PRIME - Long Length (LL), XIENCE PRIME - Core Size
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Abbott Medical Devices
Class IV Angina
The PEARL 8.0 Post-Approval Study
This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery System. The purpose of this study is to demonstrate that the 30 day mortality rate among patients who are treated with this device is less…
- Trial name
- NCT01845103
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Aphasia, Stroke
Brain Biomarkers of Response to Treatment for Apraxia of Speech
The study will use MRI brain imaging to identify brain changes associated in stroke patients after they receive speech-language treatment for their speech difficulties.
- Trial name
- SPT (NCT02046941)
- Testing
- Speech Production Treatment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- VA Office of Research and Development
Chronic Spontaneous Urticaria
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
The purpose of this study was to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remained symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab…
- Trial name
- NCT03580356
- Testing
- Ligelizumab, Omalizumab
- Where
- 183 sites in United States, Argentina and 25 more
- Volunteers
- 1,078 people
- Sponsor
- Novartis Pharmaceuticals
Cerebral Vasospasm
Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
The purpose of this study is to evaluate the usefulness of adding Milrinone to the current standard treatment for cerebral vasospasm.
- Trial name
- NCT02712788
- Testing
- Milrinone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Subarachnoid Hemorrhage, Hypertension
Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage
This study is designed to assess how rapidly and how safely Clevidipine can be used to control high Blood Pressure in patients with subarachnoid hemorrhage which is a type of brain bleed that happens because of a weak balloon…
- Trial name
- CLASH (NCT00978822)
- Testing
- Clevidipine butyrate injectable emulsion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Henry Ford Health System
Cryopyrin-Associated Periodic Syndrome
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
- Trial name
- NCT04524858
- Testing
- ATI-450
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aclaris Therapeutics, Inc.
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
Kidney Disease, Chronic
Study of Heart and Renal Protection
The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for…
- Trial name
- SHARP (NCT00125593)
- Testing
- Simvastatin 20 mg, Ezetimibe 10mg
- Where
- United Kingdom
- Volunteers
- 9,438 people
- Sponsor
- University of Oxford
Critical Limb Ischemia
Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb loss that is caused by severe compromise of blood flow to the affected extremity.
- Trial name
- STT-CLIPS (NCT02091921)
- Testing
- Ticagrelor
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Paresis, Stroke
FAME: Functional Assessment of a Myoelectric Orthosis Hand Orthoses
The primary study objective is to compare post-stroke upper extremity (UE) movement while wearing a brace called the MyoPro 2 Motion G versus UE movement while wearing a resting splint and no device in stroke survivors with…
- Trial name
- FAME (NCT04266158)
- Testing
- Myoelectric UE Device-UE Orthosis-No Device
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University
Hereditary Haemorrhagic Telangiectasia (HHT)
Diet and Hereditary Haemorrhagic Telangiectasia
Hereditary Haemorrhagic Telangiectasia (HHT) affects 1 in 5,000 people. The purpose of this study is to provide data regarding the diet and nosebleed frequency using a questionnaire. This will be filled in by people with HHT.
- Trial name
- NCT01692015
- Testing
- Questionnaire on dietary history, Questionnaire on nosebleed severity, One week food diary generated by weighing foods
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Inflammation, Coagulation
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
- Conditions
- Inflammation, Coagulation, HIV Infection
- Trial name
- TACTICAL-HIV (NCT02339415)
- Testing
- Edoxaban 30mg daily
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Hennepin Healthcare Research Institute
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Multiple Myeloma, Non-Hodgkin Lymphoma
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
To determine the maximum tolerated dose (MTD) of OPB-51602
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT01344876
- Testing
- OPB-51602
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Stroke, Acute, Aphasia
Yes/No Questionnaire for Aphasic Patients (YNQ)
Quality of care depends strongly on oral communication with patients. Stroke patients, who have language disorders, have understanding difficulties, but also have difficulties in expressing their needs and in being understood.
- Trial name
- YNQ (NCT03257696)
- Testing
- Close-ended questionnaire
- Where
- France
- Volunteers
- 152 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis